Zhaoke Opthalmology IPO Valuation: Overpriced
Some of the company’s drug candidates have the potential to become market-leading products, however, Zhaoke does not have any prior experience in...
335 Views
ECM Weekly (18th April 2021) - ByteDance Zhaoke, We Doctor, Medlive, Bio-Thera, Grab, Ngern Tid Lor
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
351 Views
Zhaoke Ophthalmology IPO: Valuation Insights
Zhaoke has launched an HKEx IPO to raise net proceeds of $239m at the mid-point of the IPO price range of HK$15.38-16.80 per share. Overall, we...
488 Views
Zhaoke Ophthalmic (兆科眼科) IPO: Rationalize the Valuation
We think the valuation is rich at the high end and the cornerstone investors' commitment left a large portion of the deal to be sold on debut.
526 Views
Zhaoke Ophthalmic (兆科眼科) Pre-IPO: Beware of Aggressive "Guidance"
We did research on its key competitor in the CsA segment and think that Frost & Sullivan grossly underestimates the competition and overestimates...
365 Views